Jessica Hergert

TOPAZ-1 results reveal promise for durvalumab administered in combination with gemcitabine and cisplatin to patients with advanced biliary tract cancer.

The social determinants of health disparities have expanded the definition of personalized medicine, Karen Winkfield, MD, PhD, said.

APVO436 appears to be safe and effective for the treatment of acute myeloid leukemia or myelodysplastic syndrome.

Tisagenlecleucel failed to improve event-free survival in the second-line setting of relapsed or refractory aggreesve B-cell non-Hodgkin lymphoma versus standard-of-care.

Real-world data on tisagenlecleucel in patients with relapsed/refractory B-cell lymphoma was consistent with the phase 2 JULIET trial, demonstrating favorable efficacy and safety.

Looking at frontline venetoclax based combinations shows promise for fit patients with CLL.

Findings from the phase 3 PADA-1 trial reveal promising progression-free survival results when treatment with fulvestrant/palbociclib follows treatment with an aromatase inhibitor plus palbociclib in a metastatic breast cancer subgroup.

Optical genome mapping may help to detect genetic abnormalities in patients with CLL.

Long-lasting responses to the triplet combination of umbralisib, ublituximab, and pembrolizumab were seen in a phase 1/2 study.

Treatment with alectinib demonstrated survival benefit in patients with non–small cell lung cancer who have resistance to crizotinib, in a retrospective study.

Compared with the median PFS reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer, the median real-world progression-free survival with durvalumab was higher.

Retrospective research suggests a survival benefit with frontline Sequential crizotinib followed by alectinib in ALK-positive non–small cell lung cancer.

In the phase 3 HERO trial of relugolix versus standard of care leuprolide in men with advanced prostate cancer, relugolix failed to significantly delay onset of castration resistance.

IGHV and TP53 remain clinical prognostic importance in patients with chronic lymphocytic leukemia, despite many prognostic markers for chemoimmunotherapy losing their clinically relevance in the context of targeted therapies for patients.

Sotorasib leads to intracranial responses in patients with KRAS G12C-mutated non–small cell lung cancer, according to an update from CodeBreaK 100.

Atezolizumab given in combination with bevacizumab led to an improvement in overall survival compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma.

The frontline combination of camrelizumab and chemotherapy resulted in improved overall survival and progression-free survival and a manageable safety profile compared with placebo plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.

The rapid issuance of clinical trial guidance, trial modifications and emphasis on inclusivity of diverse racial and ethnic patient populations have opened the door for new opportunities for decentralized clinical trials and real-world data in a post-Covid-19 world

Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression.

First-line treatment with camrelizumab, an investigational PD-1 inhibitor, plus chemotherapy elicited robust and durable clinical responses in patients with advanced squamous non–small cell lung cancer.

An analysis of the phase 3 CheckMate 9ER trial revealed that cabozantinib exposure did not significantly correlate with progression-free survival but appeared to predict high rates 2 specific adverse events.

Updated findings show how selpercatinib improves responses in patients with RET-mutant medullary thyroid cancer regardless of the prior treatment they had.

In patients with advanced or metastatic esophageal squamous cell carcinoma, Camrelizumab in combination with chemotherapy demonstrated improved overall survival and progression-free survival and a manageable safety profile as frontline therapy compared with placebo plus chemotherapy.

Mobocertinib, elicited rapid, deep, and durable responses and demonstrated a tolerable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer in a phase 1/2 study.

Administered narsoplimab in patients with high-risk hematopoietic stem cell transplant– associated thrombotic microangiopathy resulted in a response rate of 61% among all patients treated with the monoclonal antibody

Final analysis results from the phase 3 IMpower110 trial show the benefit of atezolizumab over chemotherapy in a non–small cell lung cancer subgroup.

Datopotamab deruxtecan showed antitumor activity in the treatment of patients with advanced or metastatic non–small cell lung cancer, according to updated results of the phase 1 TROPION-PanTumor01 trial.

Positive response and disease control rates were observed in 2 separate studies when patients with head and neck squamous cell carcinoma and melanoma received the combination of eganelisib and nivolumab.

In patients with previously treated advanced hepatocellular carcinoma (HCC), single-agent pembrolizumab (Keytruda) maintained numerical improvement in survival (OS), updated findings randomized phase 3 KEYNOTE-240 trial show.

The cumulative incidence of central nervous system recurrences was improved, and fewer deaths were observed with adjuvant neratinib as treatment of patients with early-stage HER2-positive breast cancer after trastuzumab-based therapy compared with placebo at 8 years of follow-up.